title: PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.
abstract: Intratumoral expression of theE. colipurine nucleoside phosphorylase (PNP) gene was originally described by our laboratories as a means to inhibit growth of solid tumorsin vivo. The approach generates purine bases that disrupt DNA, RNA, and protein synthesis, a unique mechanism when compared with all approved or experimental cancer therapeutics. Use of PNP has been validated by numerous laboratories worldwide against human tumor xenografts (lung, liver, pancreas, bladder, glioma, and prostate, among others). Data from a recently completed phase 1 clinical trial has indicated substantial anti-cancer activity in human subjects with no serious toxicities.
authors.affiliation: atlanta, georgia.
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Sorscher
authors.affiliation: atlanta, georgia.
authors.forename: Jeong S
authors.initials: JS
authors.lastname: Hong
authors.affiliation: atlanta, georgia.
authors.forename: William B
authors.initials: WB
authors.lastname: Parker
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D004926:Escherichia coli / Q000201:enzymology; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011355:Prodrugs / Q000494:pharmacology*; D011683:Purine-Nucleoside Phosphorylase / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D011355:Prodrugs; D011683:Purine-Nucleoside Phosphorylase